Podcasts about Non-Hodgkin lymphoma

In this episode of The Aging Well Podcast, Dr. Jeff Armstrong and Corbin Bruton are joined by Chris Vogelsang. Chris shares his inspiring journey through cancer diagnosis, treatment, and recovery. Diagnosed with Non-Hodgkin Lymphoma in 2008, Chris discusses the emotional impact of his diagnosis, the challenges he faced, and the importance of maintaining a positive attitude. He explains the innovative CAR-T therapy he underwent at Roswell Park Comprehensive Cancer Center in Buffalo, NY and reflects on the changes in his life post-treatment, emphasizing the value of family, relationships, and living in the moment. Chris offers advice to others battling cancer, highlighting the advancements in medical treatments and the importance of hope and support.https://www.roswellpark.org/

Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/SOHO2024/CARTCell/Video).

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support patients with non-Hodgkin lymphoma access treatment.

Four year Idaho HealingStrong Group Leader, Benjamin Canales, shares his inspiring journey from his New York roots to overcoming cancer to now leading a free support group based in holistic health. In 2016, Ben received his cancer diagnosis, and described the initial symptoms. Ben also mentions the spiritual journey that emerged as an integral part of his healing process. Learn from Ben's insights as he highlights the deep impact of faith, community, and holistic healing in his path to recovery.You will hear the reality of seeking alternative cancer treatments and the emotional roller coaster that accompanies it in his story such as the interactions with different oncologists. Discussed is the importance in understanding cancer as a symptom of deeper health issues and prioritizing nutrition. Through Ben's involvement with HealingStrong, he connects with others seeking a community and most often, alternative paths, and support from others navigating similar fears and/or challenges.Celebrate the growth of the HealingStrong Group in Idaho, and gain insight into how community and shared resources and experiences can positively impact one's healing journey. This episode is a testament to the strength found in rebuilding the body, renewing the soul, and refreshing the spirit, offering hope and encouragement for anyone on their own path to health and healing. Be inspired to take charge of your health journey and discover the resources available through the HealingStrong organization for a more holistic approach to wellness.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please consider supporting our mission by becoming a part of our Membership Program, as a monthly donor.When you do, you will receive additional resources such as: webinars, access to ALL our past and most recent conference videos, downloadables and more, as a bonus.To learn more, head to the HealingStrong Membership Program link below: Membership Program

Firefighter, cancer survivor and advocate Nick Howe shares his experiences of surviving cancer with an experimental treatment, only a few years later to require a new heart during which time a spinal stroke left him paralyzed from the waist down. Howe talks about a desire to dedicate his life in service to others initially taking the form of being a firefighter, as well as a spouse and father, but which now has assumed a new shape and vitality of purpose.Nick and Rachel Howe met initially in 2005 and later married. Nick worked as firefighter and Rachel as a teacher. In 2016, the onset of severe health issues for Nick was diagnosed as Non-Hodgkin Lymphoma that chemotherapy, immunotherapy and an autologous stem-cell transplant failed to treat. To save his life, he underwent a highly experimental therapy called CAR T-cell therapy and he has been in remission since. After welcoming their two children, in the summer of 2022, Nick experienced more illness and received a heart transplant. A few weeks later, with his new heart failing, Nick was placed in a medically induced coma during which time he had a spinal stroke that has left him paralyzed from the waist down. Nick's dedication to supporting others now includes serving as the Nebraska State Director for the Firefighter Cancer Support Network and as an ambassador for LLS and Lymphoma Research Foundation. Nick, his wife Rachel, and their two kids live in Omaha, Nebraska.

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Updates in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma — Dr Kahl (1:10) Updates in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr S Smith (33:32) CME information and select publications

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/FCS2024).

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.

In this episode, we talk with Dr. Hassan Alkhateeb, a hematologist from the Mayo Clinic Transplant Center, about CAR T-cell therapy. Dr. Alkhateeb walks us through the basics of this groundbreaking immunotherapy and how it has evolved as a treatment option for various cancers. CAR T-cell therapy involves collecting a patient's T cells and re-engineering them in the lab to target and destroy cancer cells. This therapy has shown promise in treating blood cancers like B-cell acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, multiple myeloma, and even solid tumors like synovial sarcoma.The origins of CAR T therapy date back to 2011, with the first FDA-approved product arriving in 2017. Since then, the therapy has rapidly expanded to treat more conditions. Dr. Alkhateeb explains that while CAR T is often seen as a last-resort treatment, especially in cases where patients have not responded to other therapies, early referral to CAR T specialists is becoming more common. This shift can improve outcomes, as earlier intervention allows for better preparation and potentially more effective treatment.He outlines the evaluation process for CAR T therapy, which is similar to that for bone marrow transplants but focuses on assessing the patient's overall health and suitability for cell collection rather than matching a donor. The cells are then modified in a lab, a process that typically takes two to three weeks. Dr. Alkhateeb notes that manufacturing failures are rare, affecting about 3% of cases.Post-treatment, patients must be monitored closely for side effects such as drops in blood counts, risk of infections, and specific complications like cytokine release syndrome (CRS) and neurotoxicity. These side effects can be severe but are generally manageable with the right care. Caregivers play a crucial role in this process, especially since patients need to stay near the treatment center for an extended period.Dr. Alkhateeb also shares inspiring success stories, including one patient with a particularly challenging form of leukemia who achieved remission and is now back to living a normal life. This highlights the life-saving potential of CAR T therapy and its impact on patients who otherwise have limited options.As we conclude, Dr. Alkhateeb emphasizes the importance of early referrals to specialized centers with experience in CAR T therapy. He expresses optimism about the future of cancer treatment, noting that advancements in this field are providing new hope for patients and their families. We are grateful for his insights and encourage listeners to stay informed about emerging therapies like CAR T, which are transforming the landscape of cancer care.Links:Mayo Clinic Transplant Center: https://www.mayoclinic.org/departments-centers/transplant-centerCAR T-Cell Therapy Information: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/car-t-cellFDA Approval Information on CAR T Therapies: https://www.fda.gov/news-events/press-announcements/fda-approves-first-car-t-cell-therapyThis season is made possible thanks to our sponsors:Kite, a Gilead company: http://www.kitepharma.com/and Bristol Myers Squibb's CAR T support services program:https://www.celltherapy360.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/Or visit our website at https://www.nbmtlink.org/

Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics: Introduction (0:00) Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34) Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas — Dr Lunning (21:17) Tolerability and Other Practical Considerations with CAR T-Cell Therapy — Dr Brody (40:15) CME information and select publications

The treatment landscape for non-Hodgkin lymphoma has significantly evolved over the past few decades. With groundbreaking advancements in CAR T-cell… The post Innovative Therapies: Transforming Non-Hodgkin Lymphoma Care first appeared on The Bloodline with LLS.

The treatment landscape for non-Hodgkin lymphoma has significantly evolved over the past few decades. With groundbreaking advancements in CAR T-cell… The post Innovative Therapies: Transforming Non-Hodgkin Lymphoma Care first appeared on The Bloodline with LLS.

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCO2024/BispecificLymphoma).

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:Rationale for targeting CELMoDs in NHLMechanism of action of CELMoDsKey studies and available efficacy and safety data with investigational CELMoDs in NHLKey ongoing clinical trials of CELMoDs in NHLStrategies to boost NHL clinical trial diversity among underserved communitiesPresenters: Julio C. Chavez, MD, MSAssociate MemberDepartment of Malignant HematologyICE-T Clinical Research Medical Director for Hematologic MalignanciesH. Lee Moffitt Cancer Center and Research InstituteAssociate ProfessorUniversity of South FloridaTampa, FloridaAlan Skarbnik, MDDirector, Lymphoma and CLL ProgramDirector, Immune Effector Cell Therapeutics ProgramNovant Health Cancer InstituteCharlotte, North CarolinaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb.Link to full program:https://bit.ly/45YXoZI

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hodgkin vs Non-Hodgkin Lymphoma⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17) The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45) The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43) The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48) Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19) Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25) Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44) Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19) The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17) Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59) NCPD information and select publications

Featuring perspectives from Dr Ann S LaCasce, Dr Matthew Lunning, Dr Kami Maddocks and Dr Andrew D Zelenetz, including the following topics. Introduction (0:00) Follicular Lymphoma (FL) — Dr Zelenetz (2:29) Mantle Cell Lymphoma (MCL) — Dr Lunning (32:04) Hodgkin Lymphoma (HL) — Dr LaCasce (1:00:36) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Maddocks (1:18:53) CME information and select publications

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Lymphoma).

Don't forget to take a good medical family history of your patients ! Drs Janice Dutcher and Peter Wiernik from the Cancer Research Center of New York discuss their latest work published in the January issue of JIM: Families with non-Hodgkin lymphoma and plasma cell dyscrasias in their pedigrees . A genetic contribution of cancer passed down family generations has been well described. However, the association among common B cell malignancies such as Myeloma and Non-Hodgkin's Lymphoma is less well understood. In this addition of the JIM podcast, we discuss with Drs. Dutcher and Wiernik, their findings on the importance of family history and the phenomenon of generational anticipation in well characterized patient families with Myeloma and Non-Hodgkin's Lymphoma.

Harriet Cabelly went to an emergency room because she felt dehydrated; but her visit led to a CT scan, which led to a biopsy, which led to a diagnosis of non-Hodgkin lymphoma.  Thanks to six rounds of chemotherapy and a positive attitude, Harriet achieved survivorship.  She has returned to a healthy lifestyle, which includes taking up ballroom dancing.

In this episode, veteran Teaspoon of Healing guest Joe aka "Reiki Joe" returns to the podcast. He discusses his healing journey from Non-Hodgkin Lymphoma, a form of cancer that begins in the body's lymphatic system. He describes his journey through chemotherapy, radiation, hospital stays, and recovery, and how it gave him strength and a new outlook on life.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠Non-Hodgkin Lymphoma ⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Featuring an interview with Dr Matthew Matasar, including the following topics: Rationale for the evaluation of anti-CD20 x CD3 bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL) (0:00) Incidence, severity and time course of cytokine release syndrome, neurotoxicity/ICANS and other adverse events associated with bispecific antibodies; recommended mitigation and management protocols (4:39) Activity of and similarities and differences among the various bispecific antibodies for NHL (12:20) Eligibility, efficacy and durability of response with mosunetuzumab, glofitamab, epcoritamab and odronextamab; ongoing and planned evaluations of bispecific antibodies alone and in combination with other systemic therapies (19:18) Optimal integration of bispecific antibody platforms into treatment algorithms for patients with NHL (32:12) Emerging results with bispecific antibodies for mantle cell lymphoma and chronic lymphocytic leukemia (41:51) CME information and select publications

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayBispecificNHL23)

Featuring perspectives from Professor Martin Hutchings and Dr Loretta J Nastoupil, including the following topics: Introduction (0:00) Follicular Lymphoma (2:42) Diffuse Large B-Cell Lymphoma (35:41) CME information and select publications

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 1: Role of Bispecific Antibody Therapy in Follicular Lymphoma — Loretta J Nastoupil, MD CME information and select publications

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 2: Key Data Sets with Bispecific Antibodies in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes — Martin Hutchings, MD, PhD CME information and select publications    

Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://researchtopractice.com/InsidetheIssue2023/NHL)

Delve into the complex landscape of non-Hodgkin lymphoma research, where a cure is pursued amidst a backdrop of over 100… The post Accelerating Hope for Aggressive Non-Hodgkin Lymphoma appeared first on The Bloodline with LLS.

Delve into the complex landscape of non-Hodgkin lymphoma research, where a cure is pursued amidst a backdrop of over 100… The post Accelerating Hope for Aggressive Non-Hodgkin Lymphoma first appeared on The Bloodline with LLS.

Featuring perspectives from Dr Ian W Flinn, including the following topics: Hodgkin Lymphoma Introduction (0:00) Case: A man in his late 30s with well-controlled HIV and newly diagnosed Stage IV classic Hodgkin lymphoma receives brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD) — Neil Morganstein, MD (2:30) Case: A man in his early 60s with classic Hodgkin lymphoma with a left lower lung mass and extensive regional lymphadenopathy receives brentuximab vedotin with AVD on the Phase III SWOG-S1826 trial — Ranju Gupta, MD (6:45) Mantle Cell Lymphoma (MCL) Case: A man in his late 50s with newly diagnosed MCL blastoid variant — Zanetta S Lamar, MD (16:27) Case: A man in his mid 50s with newly diagnosed Stage IV MCL — Shams Bufalino, MD (21:23) Follicular Lymphoma Case: A man in his mid 60s with incidental diagnosis of Grade IIIA follicular lymphoma after admission to the hospital for a stroke — Bhavana (Tina) Bhatnagar, DO (36:28) Case: A woman in her late 30s with extensive lymphadenopathy is diagnosed with Grade I/II follicular lymphoma and receives bendamustine/rituximab — Dr Morganstein (39:04) Diffuse Large B-Cell Lymphoma (DLBCL) Case: A physically independent man in his early 80s with DLBCL and multiple comorbidities, including cardiac issues and peripheral neuropathy, experiences disease progression after R-GCVP — Syed F Zafar MD (49:53) Case: A man in his mid 70s who presented with rapidly progressive proptosis of the left eye is diagnosed with DLBCL and receives R-CHOP and methotrexate CNS prophylaxis — Dr Lamar (55:21) CME information and select publications

Featuring a discussion on the management of non-Hodgkin lymphoma with Dr Ian W Flinn, moderated by Dr Neil Love.

Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/MTPLymphoma23/)

Looking for a holistic and integrative approach to cancer treatment? Look no further than Integrative Cancer Solutions with Dr. Karlfeldt. In this week's episode, Dr. Karlfeltdt sits down with medical oncologist, podcaster, and author Dr. Chadi Nabhan to discuss the importance of integrative and holistic methods for cancer treatment. Together, they explore the potential of AI in medicine and how it can improve precision in medical diagnoses, ultimately leading to more personalized and effective cancer treatments. From the controversial history of Roundup weed killer to the importance of understanding the support system and values of a cancer patient, this episode is packed with valuable insights and information. So, whether you're a cancer patient or simply interested in healthcare, tune in to Integrative Cancer Solutions with Dr. Karlfeldt and learn from the experts. Don't forget to visit thekarlfeldtcenter.com for more information on the center's offerings, including live consultations with cancer patients. - Dr. Chadi Nabhan on Healthcare Unfiltered- Importance of integrative and holistic cancer treatment- Oncology topics: PBMs, chemotherapy shortages, patient perspective- Dr. Nabhan's experience as an expert witness- First trial against Monsanto and glyphosate link to cancer- Investigative differential etiology in medical diagnosis- Controversy surrounding safety of glyphosate- Glyphosate's impact on cellular and chromosomal level- Challenges in cancer journey and importance of individualized treatment- Importance of support system and second opinions- Gray areas in medical oncology and communication with patients- Advancements in cancer care towards survivorship, precision medicine, and diagnostics- Future of medicine with AI in diagnostics and therapies- Promotion of Integrated Cancer Solutions with live consultations. KEY POINTS[0:0:49] Discover the shocking truth about toxic exposure with Dr. Chadi Nabhan's groundbreaking book, Toxic Exposure - now available on his website and Amazon![0:3:8] Dr. Chadi Nabhan, a renowned medical oncologist and author, is using his podcast platform to revolutionize the healthcare industry by providing expert insights and patient perspectives on the most pressing policy issues.[0:5:24] Glyphosate has been deemed a "probable human carcinogen" by the World Health Organization, with its exposure to humans linked to an alarming increase in non-Hodgkin lymphoma cases.[0:5:24] Glyphosate, the active ingredient in Roundup, has been alarmingly linked to Non-Hodgkin Lymphoma, a devastating form of cancer that affects lymph glands, the immune system, and sometimes even bone marrow.[0:5:51] Chadi Nabhan, a renowned specialist in non Hodgkin lymphoma, was urgently sought after by lawyers to provide expert testimony and vital insight on behalf of patients suing Monsanto.[0:15:32] Glyphosate, the primary active ingredient in Monsanto's widely-used Roundup herbicide, has never been subjected to long-term carcinogenicity studies, raising serious questions about its potential health risks.[0:17:22] Despite the EPA initially suspecting glyphosate of being a potential carcinogen, they were ultimately persuaded to drop their demands for further studies due to intense lobbying.[0:17:32] Discover the transformative power of words: Unlock your potential and experience extraordinary results![0:29:38] Glyphosate's dangerous effects on genetic material are undeniable, with even medical oncologists warning cancer patients to take caution when exposed to it through skin absorption.[0:37:26] Trust your gut instincts and don't be afraid to ask questions — getting a second opinion can empower you to make an informed decision.[0:41:42] As cancer survivorship rates soar, healthcare systems must prioritize the development of specialized survivorship clinics to meet the growing demand of survivors' unique needs.[0:46:43] Through careful investigative differential etiology, medical professionals can confidently and accurately identify the underlying cause of a disease or condition, empowering them to provide the most effective treatment. Connect with Dr. Chadi Nabhan https://www.carislifesciences.com/ Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. For more information about products and services discussed in this podcast, please visit www.integrativecancersolutions.com. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com.

Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Richard Newcomb, MD!

Dan Bernstein and Leila Rahimi discussed White Sox closer Liam Hendriks making his inspirational return to the mound Monday after overcoming cancer.

Join us as we highlight how pivots in therapy and self-advocacy were used to treat a young woman's diagnosis of… The post Non-Hodgkin Lymphoma:  Cancer & Pregnancy appeared first on The Bloodline with LLS.

Join us as we highlight how pivots in therapy and self-advocacy were used to treat a young woman's diagnosis of… The post Non-Hodgkin Lymphoma:  Cancer & Pregnancy first appeared on The Bloodline with LLS.

Dr. Myron Czuczman is the Chief Medical Officer and Executive Vice President of Citius Pharmaceuticals, which is developing an advanced treatment for cutaneous T cell lymphoma, CTCL, a rare form of non-Hodgkin lymphoma. The original version of their drug ONTAK has been reformulated, and I/ONTAK is now in clinical trials to confirm efficacy in controlling severe itching and improving the quality of life for patients. Myron explains, "This is a protein, a fusion protein, of interleukin-2, the whole molecule that has been fused with diphtheria toxin. With respect to any of the cells like the cells we're talking about, CTCL, it actually binds to the IL-2 receptor, internalizes, and in that manner, kills the tumor cells." "The agent ONTAK was taken off the market, and this new version, I/ONTAK or E7777, is a reformulation. It's more purified and it's about one and a half to two times more bioactive than the original ONTAK. From the clinical trials which led to our submission of the BLA recently, we've looked at the safety and efficacy, and it's consistent with the original formulation. There are no new safety issues, and it has good activity in patients, even heavily pretreated patients." "The issue here is, unfortunately, this disease, the relapsed/refractory CTCL, is incurable. The only time one has a chance to cure it is if you get it early, if you have young patients that have what we call an HLA compatible donor. In a very small number of patients, an allogeneic stem cell transplant could be curative. But the vast majority of these patients, who are elderly, are not candidates for allogeneic transplant. So, unfortunately, these are incurable individuals with bad diseases." @CitiusPharma #Cancer #Lymphoma #RareDisease #Immunotherapy $CTXR citiuspharma.com Download the transcript here

Dr. Myron Czuczman is the Chief Medical Officer and Executive Vice President of Citius Pharmaceuticals, which is developing an advanced treatment for cutaneous T cell lymphoma, CTCL, a rare form of non-Hodgkin lymphoma. The original version of their drug ONTAK has been reformulated, and I/ONTAK is now in clinical trials to confirm efficacy in controlling severe itching and improving the quality of life for patients. Myron explains, "This is a protein, a fusion protein, of interleukin-2, the whole molecule that has been fused with diphtheria toxin. With respect to any of the cells like the cells we're talking about, CTCL, it actually binds to the IL-2 receptor, internalizes, and in that manner, kills the tumor cells." "The agent ONTAK was taken off the market, and this new version, I/ONTAK or E7777, is a reformulation. It's more purified and it's about one and a half to two times more bioactive than the original ONTAK. From the clinical trials which led to our submission of the BLA recently, we've looked at the safety and efficacy, and it's consistent with the original formulation. There are no new safety issues, and it has good activity in patients, even heavily pretreated patients." "The issue here is, unfortunately, this disease, the relapsed/refractory CTCL, is incurable. The only time one has a chance to cure it is if you get it early, if you have young patients that have what we call an HLA compatible donor. In a very small number of patients, an allogeneic stem cell transplant could be curative. But the vast majority of these patients, who are elderly, are not candidates for allogeneic transplant. So, unfortunately, these are incurable individuals with bad diseases." @CitiusPharma #Cancer #Lymphoma #RareDisease #Immunotherapy $CTXR citiuspharma.com Listen to the podcast here

Oncology and hematology expert Chadi Nabhan, MD, chats with Trey Elling about TOXIC EXPOSURE: THE TRUE STORY BEHIND THE MONSANTO TRIALS AND THE SEARCH FOR JUSTICE. Dr. Nabhan served as the expert witness on Non Hodgkin Lymphoma for plaintiffs in the first three cases against Monsanto and glyphosate, the primary ingredient in their Roundup herbicide. Topics include: How Chadi's medical training took focus on oncology and hematology (1:12) Explaining Non-Hodgkin Lymphoma (4:23) What made him want testify as an expert witness against Monsanto (5:59) The shadiness behind glyphosate's initial approval in 1974 (9:58) The EPA's role in glyphosate not being labeled a carcinogen (13:47) Chad's first deposition (17:55) Initially meeting the first plaintiff, Lee Johnson (20:14) Swedish research linking glyphosate and cancer (21:45) The Who's 2015 report that shed light on glyphosate (24:48) Taking the stand in Lee John's case against Monsanto (28:29) Learning of the guilty verdicts against Monsanto (33:54) Chad's thoughts on the second and third trials (35:58) Why glyphosate is still allowed commercially, even though it's no longer sold residentially in the US (37:38) Chad's podcast, “Healthcare Unfiltered” (41:53) Ideas to help the broken US healthcare system (43:59)

Today is the day of the official launch of Chadi's first book “Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice.” Throughout the book, Chadi details his experience as an expert physician witness and the true story of the first three litigation trials against Monsanto and their herbicide "Roundup" which is linked to the development of Non-Hodgkin Lymphoma. The special guest on this unique day is the amazing icon and legend Dr. Nassim Nicholas Taleb. Dr. Taleb is beyond introduction; a best selling author of several books that contain concepts being taught in many schools. Dr. Taleb understands risk like no other and he is famous for predicting the Wall Street crash of 2008. Nassim found himself in the crosshairs with Monsanto, a story that he shares on the podcast. Dr. Taleb read “Toxic Exposure,” generously offered his opinion, and shared that he liked it and that he would recommend it to his colleagues and followers. They talk about many things, from GMOs to ghostwriting and some of the finer details of the way Monsanto cherry-picked research to fit its arguments as well as how Chadi handled himself throughout the trials. Order your copy of “Toxic Exposure” today. https://www.amazon.com/Toxic-Exposure-behind-Monsanto-Justice/dp/1421445352 Read some of Dr. Taleb's articles. https://nntaleb.medium.com Learn more about Dr. Taleb. https://en.wikipedia.org/wiki/Nassim_Nicholas_Taleb Check out his books. https://www.fooledbyrandomness.com

After several misdiagnoses, Jen Singer was diagnosed with stage 3 non-Hodgkin lymphoma. During her treatment, she was blogging about parenthood for Good Housekeeping and began writing about her cancer experience. That inspired her to become a full-time medical writer. Listen in to learn more about Jen's journey with cancer, COVID, and heart failure. You'll also hear in detail how she's used empathy to become an award-winning medical writer.   What You'll Learn: Jen Singer is introduced. (2:35) There were several misdiagnoses before Jen got diagnosed with stage 3 non-Hodgkin lymphoma. (4:05) After being rushed to the hospital, Jen got a second opinion. (9:45) When she finally got the correct diagnosis, Jen's first thoughts were her daughters. (11:00) Having an honest doctor was everything for Jen. (13:48) After recovering from COVID, Jen went into heart failure. (16:45) Jen laughs about learning the difference between the oncology floor and cardiology floor. (18:50) The term heart failure is terrifying for many people. (22:10) Anger is a common feeling when patients have multiple big diagnoses in their life. (23:00) Asking smart, specific questions about your treatment is important. (26:45) Seeing terrified patients, Jen was inspired to create "The Just Diagnosed Guides" (27:40) "How is it for you today?" is a great question to ask patients. (30:26) Healthcare providers need to be careful about what they say. (33:25)   Ideas worth sharing: "I wrote a script to call different pulmonologist offices." - Jen Singer "When you see something concerning, doctors should say, "That's odd we should investigate." - Dr. Rosalyn Morrell "The whole thing was how can I get the right treatment as fast as possible, and how can I protect my family from people saying things that aren't always helpful." - Jen Singer "Googling your symptoms is never a good idea when you don't know what you're looking for." - Jen Singer "The more dangerous the diagnosis, the more opinions you should seek." - Jen Singer "We're taught how to be healthy, not how to be sick." - Jen Singer   Resources: Rosalyn Morrell, MD: Website Jen Singer: Website

Featuring perspectives from Drs Jonathan Friedberg, Brad Kahl, David Maloney, Loretta Nastoupil and Sonali Smith, including the following topics: Diffuse Large B-Cell Lymphoma (DLBCL)  Introduction (0:00) Case: A woman in her early 60s with DLBCL with renal and subcutaneous involvement — Erik Rupard, MD (2:36) Cases: An otherwise healthy woman in her mid 80s with an orbital mass diagnosed with Stage IE DLBCL and a man in his early 80s with Stage IIIB DLBCL, GCB type and LVEF 35% to 40% due to prior myocardial infarction and coronary artery disease — Bhavana (Tina) Bhatnagar, DO and Yanjun Ma, MD (7:10) Dr Friedberg presentation (11:54) Follicular Lymphoma  Case: A man in his late 60s with progressive Grade I/II follicular lymphoma after observation for many years — Neil Morganstein, MD (29:07) Case: A woman in her early 60s with Grade II follicular lymphoma who received bendamustine/rituximab and maintenance rituximab — Jennifer L Dallas, MD (33:11) Dr Nastoupil presentation (38:36) Hodgkin Lymphoma  Case: A woman in her early 80s with newly diagnosed classical Hodgkin lymphoma — Kapisthalam (KS) Kumar, MD(51:21) Cases: A woman in her late 30s with newly diagnosed classical Hodgkin lymphoma and a man in his early 60s with newly diagnosed Stage IV classical Hodgkin lymphoma who receives brentuximab/vedotin with AVD (doxorubicin/vinblastine/dacarbazine) — Susmitha Apuri, MD and Amany R Keruakous, MD, MS (55:21) Dr Smith presentation (1:10:17) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma   Cases: A man in his late 50s who presents with a large cecal mass and mesenteric adenopathy and is diagnosed with “double hit” DLBCL and a woman in her early 70s with DLBCL treated with R-CHOP, now with progressive disease 6 months later — Vignesh Narayanan, MD and Rahul Gosain, MD (1:14:56) Case: A woman in her early 70s with rapid relapse after R-CHOP then R-ICE (rituximab/ifosfamide/carboplatin/etoposide) and ASCT who achieves a complete response with CAR T-cell therapy but experiences significant pancytopenias — John Yang, MD (1:22:10) Dr Maloney presentation (1:25:24) Mantle Cell Lymphoma (MCL)  Case: A man in his late 70s with high-risk relapsed MCL after BR and maintenance rituximab x 3 years — Raman Sood, MD (1:39:10) Case: A man in his mid 80s who received prior treatment for prostate cancer and presents with low-volume indolent MCL with a TP53 mutation — Spencer H Bachow, MD (1:42:47) Dr Kahl presentation (1:45:29) CME information and select publications

Jen Singer is a ghostwriter, speechwriter, writing coach and developmental editor with a whole bunch of stories to tell.  As a writing coach at TEDx Cambridge, one of the world's largest independently-organized TED platforms, she has helped dozens of speakers get their stories “on their feet” in front of an audience. Whether writing for the page or the stage, she believes the message is the medium. “A good speech is a good performance,” she says, “but it starts with good writing.”  One of the original “mom bloggers,” Jen wrote on parenting issues for over fifteen years on www.mommasaid.net – a gig that led to a two-year stint as the author of the “Good Grief” blog for Good Housekeeping. Over the years, she has also written for The New York Times, The Wall Street Journal, Parents, Woman's Day, and McSweeney's, while writing several books of her own and launching her career as a book doctor and collaborator.  Somewhere in there, coinciding with her own diagnosis of Stage 3 Non-Hodgkin Lymphoma, she shifted her focus from parenting issues to medical issues – a shift that came about while she was blogging on potty training issues for Pull-Ups.  “June is National Potty-Training Month,” she recalls, “and I was in the hospital measuring my urine for my doctor…It was surreal.”   Jen saw the humor in that surreal moment, but she also saw opportunity, and she started working as a medical writer for NYU Langone Health, Northwell Health, Hospital for Special Surgery, and Weill Cornell Medicine. Her experience as a cancer survivor led her to write a series of e-books called "The Just Diagnosed Guides: What You Need to Know Now (without Googling it)," designed to help patients and families navigate the uncertainty that finds them after a difficult diagnosis. In addition to her work with TEDx Cambridge, Jen also works as a writing coach and editor for Heroic Public Speaking, a leading public speaking training program, where she has worked with a wide range of clients, including CEOs, Olympic athletes, educators, fighter pilots, marketing experts, physicians, psychologists, Ivy League researchers and professors, and undercover FBI agents. For more on Jen Singer, visit her official website, like her Facebook page, and follow her on Twitter and Instagram. Please support the sponsors who support our show. Daniel Paisner's Balloon Dog Film Movement Plus (PODCAST) | 30% discount Libro.fm (ASTOLDTO) | 2 audiobooks for the price of 1 when you start your membership The Thoughtful Bro podcast, hosted by Mark Cecil Pop Literacy, hosted by Jennifer Keishin Armstrong and Kimberly Potts Writer's Bone, hosted by Daniel Ford